CIDRAP – Vaginal Estrogen Could Reduce UTIs, Hospitalization

Tier 2: Professional organization or credentialed expert guidance
Publisher: CIDRAP – University of Minnesota Center for Infectious Disease Research and Policy · Published: August 9, 2026 · Accessed: August 15, 2026

Visit the source ↗

Claims this source supports

• Declining estrogen during perimenopause and menopause makes UTIs more likely; urgency, UTIs, vaginal atrophy, pain with sex, and vaginal dryness fall under genitourinary syndrome of menopause (GSM), which affects 13% to 87% of women (2024 Annals of Internal Medicine editorial).
• A 2025 study in JAMA Network Open found only 9% of female Medicare recipients with GSM who had a prescription for vaginal estrogen actually filled it – the 'most eligible patients never fill the prescription' gap.
• Case example (Karen, 65, Pittsburgh): gynecologist diagnosed vaginal atrophy, told her it was 'completely reversible with the usage of vaginal estrogen' and that it would alleviate UTI symptoms – which it did.
• Vaginal estrogen is a low-dose local product (cream, tablet, ring), distinct from systemic HRT; Mayo Clinic's Dr. Stephanie Faubion reports vaginal forms more effective than systemic estrogen for genitourinary symptoms with no associated increase in breast cancer or heart disease risk.